drugset / Trial / NCT01665404

A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers

NCT01665404

Phase 1 Completed 16 enrolled Hoffmann-La Roche
Non-randomizedCrossoverOpen-label

Summary

This single-center, open-label, cross-over study will evaluate the effect of fluvoxamine on the pharmacokinetics of RO4917523 in healthy volunteers. Healthy volunteers will receive a single dose of RO4917523 alone and in combination with multiple doses of fluvoxamine in a cross-over design. The anticipated time on study treatment is 40 days.

Timeline

Start
2012-07
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Basimglurant Small molecule
Subject Fluvoxamine Unknown

Indications

No indication recorded.